Hematological Malignancies Drugs Market Exclusive Trends Analysis with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hematological Malignancies Drugs Market Trends and Dynamics, Clinical Trial/Pipeline Analysis, Industry Competition Analysis, Revenue Forecast To 2030."The Hematological Malignancies Drugs Market Size is valued at 15.35 Billion in 2022 and is predicted to reach 42.78 Billion by the year 2030 at a 13.9 % CAGR during the forecast period for 2023-2030.
Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/1211
Hematological malignancies are the cancer types that affect the blood, bone marrow, and lymph nodes. Myeloma, leukemia, and lymphoma are the three types of hematological malignancies, and lymphoma is the most common blood cancer. Small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells are among the emerging targeted therapies that have improved clinical outcomes for blood malignancies.
The growth of the Hematological Malignancies Drugs Market can be attributed to factors, such as the rising prevalence of blood malignancies, rising healthcare expenditure, increasing R&D activities to develop novel cancer therapies, adoption of precision medicine in the field of hematological malignancies, increasing number of drug approvals for treating different types of hematological malignancies, growing innovations in leukemia and lymphoma targeted therapies. According to the Blood Cancer Statistics 2021, around 459,058 leukemia cases and more than 962,304 lymphoma cases are predicted to diagnose in the United States. Also, as per Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 Hodgkin (HL) and 77,240 Non-Hodgkin (NHL) Lymphoma cases. Thus, the rising incidences of leukemia, lymphoma cases are estimated to upsurge the demand for this market in the coming future.
However, the high cost of treatment and products, adverse effects of therapeutics, unfavourable medical reimbursement policies, and safety concerns are estimated to restrain the market expansion in the upcoming years.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1211
Regionally, North America is projected to generate the highest CAGR in this market over the forecast period due to the rising R&D activities in cancer research. The Asia Pacific region also majorly contributes to the growth of the Hematological Malignancies Drugs Market. The increasing cancer research funding, high prevalence of blood malignancies, and the rising need for effective therapies contribute to the market growth.
Major market players operating in the hematological malignancies drugs market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, among others.
Key developments in the market:
• In October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML) in two distinct indications.
• In September 2021, AbbVie and Genmab A/S published the results of the dose-escalation part of the Phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose-escalation and cohort expansion clinical trial eValueating the safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL).
• In March 2021, Sanofi SA received the US FDA approval for Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
• In August 2020, GlaxoSmithKline plc received US FDA approval for BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for patients with relapsed or refractory multiple myeloma.
• In July 2020, Takeda Pharmaceutical Co. Ltd. received US FDA approval for pevonedistat, an investigational cancer drug for treating higher-risk myelodysplastic syndromes.
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1211
Market Segments
Global Hematological Malignancies Drugs Market, by Drugs, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Blincyto (Blinatumomab)
o Besponsa (Inotuzumab Ozogamicin)
o Lumoxiti (Moxetumomab Pasudotox)
o Mylotarg (Gemtuzumab Ozogamicin)
o Opdivo (Nivolumab)
o AiRuiKa (Camrelizumab)
o Tyvyt (Sintilimab)
o Tislelizumab
o Gazyva (Obinutuzumab)
o Zynlonta (Loncastuximab Tesirine-lpyl)
o Darzalex (Daratumumab)
o Blenrep (Belantamab Mafodotin-blmf)
o Keytruda (Pembrolizumab)
o Adcetris (Brentuximab Vedotin)
o Arzerra (Ofatumumab
• CAR-T Cell Therapy
o Tecartus (Brexucabtagene Autoleucel)
o Kymriah (Tisagenlecleucel)
o Yescarta (Axicabtagene Ciloleucel)
o Breyanzi (Lisocabtagene Maraleucel)
o Abecma (Idecabtagene Vicleucel)
Global Hematological Malignancies Drugs Market, by Pipeline Products, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Teclistamab
o Iomab-B
o Ublituximab
o CS1001
• CAR-T Cell Therapy
o Ciltacabtagene Autoleucel (JNJ-68284528)
Global Hematological Malignancies Drugs Market, by Indications, 2022-2030 (Value US$ Mn)
• Leukemia
o Acute Lymphoblastic Leukemia
o Chronic Lymphoblastic Leukemia
o Acute Myeloid Leukemia
• Lymphoma
o Hodgkin's Lymphoma
o Non-Hodgkin's Lymphoma
• Multiple Myeloma
Global Hematological Malignancies Drugs Market, by region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• The U.S.
• Canada
Europe Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of clinical trial/pipeline products for the global hematological malignancies drugs market
To receive a market overview and future trends of the hematological malignancies drugs market
To analyze the hematological malignancies drugs market drivers and challenges
To get information on the Hematological Malignancies Drugs Market size (Value US$ Mn) forecast to 2030
Major investments, mergers & acquisitions in the Hematological Malignancies Drugs Market industry
For More Information: https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market--/1211
Other Related Reports Published by InsightAce Analytic:
Immuno-oncology Cell Therapy Market
Global Allogeneic Cell Therapy Manufacturing Market
Global CAR T-Cell Therapy For Multiple Myeloma Market
Global Allogeneic Cell Therapies Market
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Asia: +91 79 72967118
Tel : +1 551 226 6109
Email: info@insightaceanalytic.com
Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hematological Malignancies Drugs Market Exclusive Trends Analysis with Forecast to 2031 here
News-ID: 3321818 • Views: …
More Releases from Insightace analytic
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031"
The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%…
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031
"Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by…
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals…
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031"
The Global Data Center Liquid Cooling Market is estimated…
More Releases for Hematological
Global Hematological Malignancies Biotherapeutics Market
According to a new market research report published by Global Market Estimates, the Global Hematological Malignancies Biotherapeutics Market is projected to grow at a CAGR value of 10.8% from 2022 and 2027. The hematological malignancies biotherapeutics market is driven mainly by the growing incidence of blood cancer, increasing investment in cancer research, growing cancer awareness initiatives, and the growing number of specialized cancer treatment facilities.
Browse 151 Market Data Tables and…
Advanced Technologies Of Hematological Disorders Market 2017
Albany, NY, 23rd November : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" globally.
The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia.
Get PDF for…
Hematological Cancers Market 2017 Trends and Review
The Global Hematological Cancers Market Research Report 2017 to 2022 renders deep perception of the key regional market status of the Hematological Cancers Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan.
Request for sample of Hematological Cancers Market research report @ https://goo.gl/BeUKBz
Split by product type,…
Hematological Malignancies Market Is Expected To Profits
Global Hematological Malignancies Market: Snapshot
Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for…
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position…
Increasing Incidence of Hematological Cancers is Expected to Boost the Global He …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system.
Myeloma is a cancer associated with the plasma of the white blood…